Ozempic and Wegovy Officially Taken Off Shortage List
The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain stable.
Stock.adobe.com
FDA officially declared that popular GLP-1s Wegovy and Ozempic are no longer in shortage.1
The two drugs soared in popularity in recent years due to their potential to help with weight-loss. The medicines were originally developed as diabetes treatments but have since become more widely known as weight-loss assistance drugs.
Due to the high demand, Novo Nordisk limited new prescriptions starting back in 2022. Those limitations eased in 2024, although demand was still putting pressure on the supply chain. According to a new statement from FDA, it appears that Novo Nordisk is able to meet the demand.
In a statement on its website, the agency wrote, “FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent and limited localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies.”
The statement continues, “To avoid unnecessary disruption to patient treatment, the agency does not intend to take action against compounders for violations of the FD&C Act arising from conditions that depend on semaglutide injection products’ inclusion on FDA’s drug shortage list.”
FDA continued that statement by clarifying its regulations on compounding medications under both sections 503A and 503b of the FD&C act.
FDA also provided a statement from Robert Fischer, director of regulatory affairs at Novo Nordisk, which goes into further detail about the current state of the supply chain.2
Fischer writes, “As a result of this review, we conclude that the information and data Novo Nordisk has provided to FDA demonstrate that Novo Nordisk’s supply is currently meeting or exceeding demand for its semaglutide injection products, and that Novo Nordisk has developed reserves that it now holds in its finished product inventory in addition to significant units of semi-finished product, such that supply will meet or exceed projected demand. After carefully evaluating the information from sources other than Novo Nordisk, we find that it has important limitations. We conclude that this information does not undermine or outweigh the evidence demonstrating that Novo Nordisk’s supply is currently meeting or exceeding demand and that, based on our best judgment, it will meet or exceed projected demand.”
Sources
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. FDA. February 21, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Fischer, Robert. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy). February 21, 2025. www.fda.gov/media/185526/download?attachment
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Eikon Therapeutics Raises $350 Million in Series D Funding to Advance Oncology Pipeline
February 26th 2025The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, automation, and data science that drives innovation in drug development.
